Publications by authors named "Tomohiro Onoue"
This study estimated the incidence of moderate-to-severe drug-induced interstitial lung disease (ILD) among patients with breast cancer in Japan. We analyzed a large nationwide database of patients with breast cancer treated with anticancer therapies between 2009 and 2022. ILD was identified using diagnostic codes and treatment records.
View Article and Find Full Text PDFArticle Synopsis
- - Daprodustat is an oral medication being compared to darbepoetin alfa (an existing treatment) for its effectiveness in treating anemia in Japanese patients undergoing hemodialysis due to chronic kidney disease (CKD).
- - The study, a phase 3 randomized trial, found that daprodustat maintained hemoglobin levels similarly to darbepoetin alfa, showing it to be noninferior, meaning it is just as effective.
- - Additionally, daprodustat demonstrated a greater decrease in hepcidin levels and an increase in total iron-binding capacity, suggesting enhanced iron metabolism compared to darbepoetin alfa, with most participants experiencing similar rates of side effects.
Article Synopsis
- - Daprodustat is a drug that helps stimulate red blood cell production (erythropoiesis) by mimicking the body's response to low oxygen levels, making it a potential treatment for anemia related to chronic kidney disease (CKD).
- - A study involving 64 healthy Japanese males tested two different tablet strengths of daprodustat to check if they were bioequivalent and how food impacted its absorption in the body.
- - Results showed that the 2-mg and 4-mg daprodustat tablets were bioequivalent, and eating a standard meal did not significantly affect how the drug was processed in the body, with the drug being well tolerated among participants.
Article Synopsis
- Daprodustat is an oral medication aimed at treating anemia in patients with chronic kidney disease, specifically focusing on those undergoing hemodialysis and not using erythropoiesis-stimulating agents.
- In a 24-week clinical trial, 28 Japanese patients were given daprodustat starting at 4 mg daily, which successfully raised their hemoglobin levels from a baseline of 9.10 g/dL to the target range of 10.0 to 12.0 g/dL by week 8.
- Throughout the study, daprodustat maintained these hemoglobin levels without introducing any new safety issues among the participants.
We developed a pravastatin derivative, sodium (3R,5R)-3,5-dihydroxy-7-((1S,2S,6S,8S)-6-hydroxy-2-methyl-8-((1-[(11)C]-(E)-2-methyl-but-2-enoyl)oxy)-1,2,6,7,8,8a-hexahydronaphthalen-1-yl)heptanoate ([(11)C]DPV), as a positron emission tomography (PET) probe for noninvasive measurement of hepatobiliary transport, and conducted pharmacokinetic analysis in rats as a feasibility study for future clinical study. Transport activities of DPV in freshly isolated rat hepatocytes and rodent multidrug resistance-associated protein 2 (rMrp2; human, MRP2)-expressing membrane vesicles were similar to those of pravastatin. Rifampicin diminished the uptake of DPV and pravastatin by the hepatocytes, with similar inhibition potency.
View Article and Find Full Text PDF